One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Kymera Therapeutics just hit that mark, with a jump from 80 to 83 Friday.
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks often have an 80 or higher RS Rating as they begin their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
While now is not an ideal time to buy shares, see if the stock is able to establish and enter a buying range in heavy trade.
The company showed 0% earnings growth last quarter, while sales growth came in at -21%.
The company earns the No. 141 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
